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1112-86 Performance of the Thrombolysis in Myocardial 
infarction ST Elevation Myocardial Infarction Risk Score 
in Elderly Patients 
Saif S. Rathora, Kevin P. Weinfurt, JoAnne M. Foody, Harlan M. Krumholz, Yale 
University School of Medicine, New Haven, CT, Qualidigm, Middletown. CT 
Background: The Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial 
infarction (STEMI) mortalitv risk score was developed in a randomized trial copulation: its ~ 
accuracy in community-based elderly STEMI patients is unknown. 
Methods: The Coooerative Cardiovascular Proiect iCCPI database was used to deter- 
I  I  
mine the prognostic performance of the TIMI score in patients age 65 years and older 
hospitalized with confirmed STEMI in 1994-96 (n=47,682). Accuracy of admission TIMI 
scores (range 2-14. lower scores indicate less risk) was assessed by determining cali- 
bration (visual inspection of calibration plots and Hosmer-Lemeshow goodness of fit (gof) 
test, p<O.O5 indicates poor fit) and discrimination (c-statistic, ~~0.50 for no discrimination, 
c=l .OO for perfect discrimination) from a logistic regression model for 30-day mortality. 
Differences in TIMI soora performance bePween patients who did and did not receive 
acute reperfusion therapy (RT) were tested using a TIMI score x RT interaction term. 
Thirty-day mortality rates in CCP were compared with published TIMI score rates. 
Results: The median TIMI score was 6 (25th.75th percentile 4.6) and the 30-day mortal- 
ity rate was 20.1%. Mortality rates were higher among patients with higher TIMI scores 
(TIMI score 2: 4.4% vs. TIMI score >6: 35.6%. p<O.OOl for trend), but the TIMI score pro- 
vided only modest discrimination (c=O.67) and poor calibration (gof p<O.OOOl). TIMI 
score accuracy varied by use of RT (pcO.001 for TIMI score x RT interaction) as calibra- 
tion (gof p=O.O31) and discrimination (c=O.69) Were better among patients who received 
RT than patients who did not receive RT (gof p<O.OOl. c=O.63). TIMI score 30-day mor- 
tality rates in CCP were higher than published TIMI estimates (PcO.001, e.g., TIMI score 
2: 4.4% CCP vs. 2.2% published rate). 
Conclusion: The TIMI score provides only modest prognostic discrimination and calibra- 
tion among elderly patients hospitalized with STEMI, particularly those who do not 
receive RT. Published TIMI 30-day mortality rates underestimated actual 30.day mortal- 
ity rates. Our findings highlight the limitations of applying randomized trial-derived risk 
scores to community populations. 
1112-87 Differences Between TIME (Trial of Invasive Versus 
Medical Therapy in Elderly Patients With Chronic 
Angina) and Registry Patients, and Impact on Outcome 
Matthias E. Pfisterer, Stefan Wyrsch, Gabriela Kuster, Lukas Schdb, Leticia Grize, 
Raban V. Jeger, Christoph Kaiser, Peter T. Buser, The TIME Investigators, University 
Hospital Basal, Basel. Switzerland 
Background: In trial settings, patients selected for studies often are less sick than regis- 
try patients making study results not generalizable. In the TIME study (Trial of Invasive 
vs. Medical Therapy in the Elderly with chronic angina), patients 275 years of age were 
included based on clinical presentation (angina CCS (Canadian Cardiac Society) class 2 
II despite 2 2 drugs) and not based on coronary anatomy. 
Methods: To assess whether these inclusion criteria led to a different patient population 
than usually referred for invasive management, all 166 TIME patients of 4 hospitals (62% 
of TIME) were compared at baseline with all 201 patients of the same hospitals referred 
for coronary angiography during the study period with TIME inclusion criteria but no con- 
sent (REFER patients). One year outcome regarding major cardiac events (MACE: 
death, infarction (Ml) and hospitalisations for acute disease (ACS) were compared 
between invasive TIME and REFER patients. 
Results: In comparison to REFER patients, TIME patients were older (79+ 3 vs. 76+ 2 
years, p<.OOl). more women (44 vs. 35%. p=.O7), had more angina (class 3.1 vs. 2.3+ 
1.2, pc.OOOl), more antianginal drugs/patient (2.6 vs. 2.1, pc.0001) and somewhat less 
prior revascularisations (20 vs. 26%, p=.O7); however, ejection fraction and distribution of 
vessel disease were similar. Regarding one-year outcome, there were no significant dif- 
ferences between invasive TIME and REFER patients in symptoms, quality of live and 
MACE: rate of death 9.6 vs. 13.6%. death/Ml 14.9 vs. 15.2%, MACE 22.3 VS. 18.7% (all 
p>.4), and this remained not significant after adjustment for baseline differences. 
Conclusions: This analysis shows that coronary disease in patients selected for TIME 
was not less severe than in REFER patients, and TIME patients needed more drugs to 
treat angina which was more severe than in REFER patients. Since outcome events 
were also similar in invasive TIME and REFER patients, reported results of TIME should 
be relevant to most patients of this age group. 
1112-88 Acute and Long-Term Outcomes of Multivessel Stenting 
in Patients Aged 80 Years 
Yoshio Kobavashi. Roxana Mehran, Makoto Hirose, George Dangas, Alexandra J. 
Lansky, Gregg W. Stone, lssam Moussa, Gary S. Mint.& Michael 8. Collins, Edward 
Kreps, Jeffrey W. Moses, Martin B. Leon, Cardiovascular Research Foundation, New 
York. NY 
Background: Multivessel stenting is routinely performed at a single procedure even in 
the very elderly. Clinical outcomes of multivessel stenting in this advanced age group 
have not been fully evaluated. 
Methods: Multivessel stenting was performed in 969 patients with 2,919 lesions. 
Patients were classified into two groups according to age: (1) ~60 years old (894 
patients, 2,676 lesions) and (2) Zt30 years old (75 patients, 241 lesions). 
Results: 
Female (%) 
Diabetes mellitus (%) 
Reference (mm) 
Pre MLD (mm) 
Post MLD (mm) 
Procedure Q-MI (%) 
Proc non-Q Ml (%) 
In-hosp CABG (%) 
In-hosp death (%) 
Angio. sucoess (%) 
Bleeding camp (%) 
Vascular camp (%) 
Neuro. event (%) 
Pulmonary edema (%) 
1 -month MACE (%) 
l-year death (%) 
l-year MI (“/) 
1 -year TLR (%) 
1 -year MACE (%) 
-caramc aeath. Anglo=anglographlC, comp=complaatlon, Neuro=neurological, 
MACE=major adverse cardiac event, MLD=minimum lumen diameter, Proc=procedure, 
TLR=target lesion revascularization. 
Conclusions: Multivessel stenting in pts Z60 yrs of age is associated with increased 
acute and long-term complications. This translates into a higher l-month and l-year 
MACE rate even though the need for repeat revascularization tends to be lower. 
26 53 co.01 
32 35 0.6 
2.92*0.77 2.8leO.56 0.3 
l.lliO.65 0.95ti.64 0.2 
2.76 iO.80 2.74kO.73 0.9 
0.1 0 1 .o 
al 33 <O.Ol 
0.7 0 1.0 
0.3 1.3 0.3 
99.5 100 1.0 
3.6 4.4 0.7 
2.6 4.1 0.4 
2.4 6.6 0.04 
1.7 8.1 <O.Ol 
2.6 6.7 0.046 
6.6 25 co.01 
6.9 13.6 0.07 
21.6 15.5 0.27 
26 35 0.08 
40 280 p value 
POSTER SESSION 
1135 Ventricular Remodeling: Hypertrophy 
Monday, March 31, 2003, 3:00 p.m.500 p.m. 
McCormick Place, Hall A 
Presentation Hour: 4:00 p.m.-%00 p.m. 
1135-59 Inhibition of P38 Mitogen-Activated Protein Kinase 
Protects the Heart Against Cardiac Remodeling in Mice 
With Heart Failure Due to Myocardial Infarction 
Yun-He Liu PI Dahai Wang, Nour-Eddine Rhakb. Xiao-Ping Yang, Jiang Xu, AI-Li Yu, Amy 
E. Rudolph, Oscar A. Carretero, Henry Ford Hospital, Detroit, MI, Pharmacia. St. Louis, 
MO 
Background: mitogen-activated protein kinases (MAPKs) have emerged as an impor- 
tant pathophysiological regulator during the development of heart failure. ~36 MAPK 
activity has been shown to be elevated in cardiac hypertrophy and heart failure. We used 
a mouse model of myocardial infarction (Ml) to test the hypotheses that 1) inhibibon of 
p36 MAPK activity may improve cardiac function and myocardial morphology after MI; 
and 2) combined treatment with a p38 MAPK inhibitor and an angiotensin-converting 
enzyme inhibitor (ACEi) provides further cardioprotection. 
Methods Ml was induced in C57BU6J mice by ligating the left anterior descending cor- 
onary artery. Two weeks later, they were treated for 12 weeks with a) vehicle, b) SC-409, 
a pyrazole class of p38 MAPK inhibitor (p38i; 30 mg/kg/day in food), c) ACEi (enalapril; 
20 mg/kg in drinking water) or d) both p38i and ACEi. Echocardiography was performed 
and systolic blood pressure (SBP) measured before Ml and weekly thereafter. At the end 
of the study, interstitial collagen fraction (ICF) and myocyte cross-sectional area (MCSA) 
were examined histologically. 
Results We found that 1) in vehicle-treated mice with heart failure, left ventricular ejec- 
tion fraction (LVEF) and cardiac output (CO) decreased while LV mass, diastolic dimen- 
sion (LVDd), ICF and MCSA all increased significantly; 2) inhibition of p36 MAPK 
sigmficantly improved cardiac function and remodeling, as evidenced by increased LVEF 
(vehicle vs p36i: 20.3 f 1.6 YS 35.4 * 2.2%; p< 0.001) and CO (11.8 * 0.9 vs 19.1 * 1.2 
ml/mln; p < 0.01) and decreased LV mass (177 t 12 vs 106 * 3.4 mg; p < O.OOl), MCSA 
(345 * 10 “s 266 * 5 vm2; p < 0.001) and ICF (12.7 + 0.6 YS 9.8 * 0.4 %; /I < 0.001); and 
3) ACEi and p36i monotherapy each had similar beneficial effects. Combined treatment 
with p36i and ACEi provided only limited added benefit. 
Conclusion: Our data suggest that inhibition of ~38 MAPK provides significant cardio- 
protection in mice with heart failure post-MI. 
1135-60 Simvastatin Restores Contractile Function and 
Reduces Cardiac Remodeling in a Genetic Model of 
Cardiomyopathy 
Juan C. Osorio, Seena S. Abraham, Beth D. Kaufman, Paloma De Prada, Shunichi 
Homma. James K. Liao. Seema Mital. Columbia Universitv. New York. NY, Brigham 8 
Women’s Hospital, Bosion, MA 
Background: 82 kinin receptor (B2R) stimulation activates endothelial nitric oxide syn- 
thase (eNOS). Disruption of the B2R results in dilated cardiomyopathy which may be 
related to decreased NO. Simvastatin (Sim) increases cardiac NO production through 
increased expression and/or phosphorylation of eNOS. We evaluated the ability of Sim to 
upregulate NO production and reduce contractile dysfunction and cardiac remodeling in 
mice lacking the B2R. 
Methods: 2 month old, male mice with genetic disruption of the B2R (BPRKO) (n=16) and 
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wild-type controls (BZRWT) (n=ZO) were studied. Half the mice in each group were 
treated with Sim (ZOmg/kg/day oral) for 6 weeks. 2D echocardiography was performed at 
baseline and 6 weeks to measure cardiac function and dimensions. At 6 weeks, eNOS, 
phospho-eNOS and phospho-AM expression was measured in myocardium. Myocardial 
sections were stained to detect eNOS in microvessels. 
Results: BPRKO mice developed LV hypertrophy compared to WT (LV mass 6.6kO.3 YS 
5.6kO.3 mg/m2; mass/volume ratio 0.7r0.01 vs 0.63+0.02) with increase in LV volume 
(9.6*0.4 vs 8.0i0.5 ml/m2), LV end-systolic diameter (16.3+0.9 vs 13.4+0.6 crnIm2) and 
decrease in LV shortening fraction (SF 48+2% vs 57i2%) (p.zO.05 vs WT). Sim treatment 
lowered LV mass (5.6~2 mg/m2), volume (6.2kO.3 mllm2). systolic diameter (1.4iO.5) 
and increased SF (57*1%) in KO mice compared to untreated group (p<O.Ol). Sim did 
not alter LV function in WT mice. eNOS expression was preserved in KO mice. Phospho- 
eNOS expression was lower in KO mice compared to Wl (p=O.O5). Sim treatment 
decreased eNOS (p=O.O06) but increased phospho-eNOS expression (~~0.05) com- 
pared to untreated KO. Phospho-Akt, which phosphorylates eNOS, was also higher in 
the Sim treated KO. lmmunostaining localized eNOS to the coronary vascular endothe- 
lium in both KO and WT mice. 
Conclusion: Disruption of the BZR results in reduced eNOS activation and progressive 
cardiac remodeling and dysfunction. Sim reduces contractile dysfunction and cardiac 
remodeling by increasing AM-mediated eNOS phosphotylation. Since B2R and eNOS 
expression is reduced in human heart failure, this novel effect of Sim may be pote$ally 
beneficial in the treatment of heart failure. 
1135-61 Changes in Borderzone Curvature Herald Adverse 
Remodeling After Myocardial Infarction: A Contrast 
Echocardiographic Study 
Beniamin M. Jackson, Joseph H. German, Ill, Yoshiharu Enomoto, Martin G. St. John 
Sutton, L. H. Edmunds, Jr., Robert C. German, Hospital of the University of 
Pennsylvania, Philadelphia, PA 
Background 
The borderzone (BZ) - the myocardium adjacent to an infarct characterized by normal 
perfusion but decreased contractility has been shown to expand chronically, as remcd- 
cling occurs and congestive hearl failure (CHF) develops. We hypothesize that early 
increases in BZ stress Initiate this phenomenon. 
Methods 
We studied an ovine model of anteroapical myocardial infarction (MI) that results in CHF 
wer 6 weeks. Contrast echocardiography was used to image the lefl ventricle (LV) in 
long-axis. In the ventricular septum, a discrete infarct line (red in figure) could be seen in 
all animals (n=4) at 1 hr postinfarction. The BZ was defined as the contrast-perfused 
myocardium adjacent to this infarct line. The wall thickness (h) and the LV endocardial 
curvature (K) were determined at end systole (ES) before and after infarction. 
Results 
The BZ endocardial contour was concave towards the cavity at baseline, with K = 0.26 
cm-’ t 0.06 cm’. Postinfarction. BZ endccardial contour was convex towards the cavity, 
with K = 0.61 cm-’ + 0.15 cni’(p < .Ol). BZ h increased from 1.06 cm f 0.17 cm at base- 
line to 1.27 cm f 0.21 cm at 1 hr (p < 0.05). 
Conclusion 
In a model of progressive LV remodeling, geometric changes consistent with decreased 
series resistance and increased load-derived wall stress were measured in the BZ imme- 
diately after MI. These findings suggest that alterations in LV conformation contribute to 
BZ expansion, and that contrast echocardiographic studies may allow prediction of pro- 
gresswe LV remodeling and CHF. 
apex 
D LV cavity BZ 
1135-84 Impact of Autologous Skeletal Myoblast 
Transplantation on Hemodynamics and Left Ventricular 
Function in Repeated Coronary Microembolization- 
Induced Heart Failure in Awake Dogs 
Kun-Lun He, Hua Zhou, Geng-Hua Yi, Eva M. Becker, Warren Sherman, An-Guo Gu, 
Jack Harvey, Race Kao, GE-Ping Zhang, Satoshi Mohri, Myung J. Lee, Jie Wang, Daniel 
Burkhoff, Mount Sinai School of Medicine, New York, NY, Columbia University, New 
York, NY 
Background: Previous studies suggested that autologous skeletal myoblast tansplanta- 
tion (ASMT) improves left ventricular (LV) function in small animals following myocardial 
infarction. We tested the effects of ASMT on hemodynamics and LV function in repeated 
coronary microembolization-induced chronic heart failure (CHF) in conscious dogs. 
Methods: 13 dogs were chronically instrumented with LV and aortic pressure sensors 
and mid-myocardial sonomicrometry crystals for LV volume determination. Pneumatic 
Cuff was placed to perform Inferior vena cava occlusion. Each dog underwent baseline 
assessment in conscious state. CHF (20-30% reduction in dP/dt,,, and LV end diastolic 
pressure>=1 6mmHg) was created by daily coronary microembolizations via a chronically 
implanted coronary catheter. A skeletal muscle biopsy was performed and myoblasts 
were isolated and expanded. 2.6X10*-to 7.6X1@ myoblasts were injected into the 
infracted region of 6 dogs after establishment of CHF. Saline injection (sham) was per- 
formed in 5 control dogs. Animals were evaluated every 2 weeks for up to 10 weeks. 
Hemodynamic measurement included dPld&, and mean aoriic pressure. Ejection frac- 
tion was determined by echocardiography. Ees (LV contractility) and alpha (LV stiffness) 
were determined by pressure volume analysis. 
Results Compared to saline injection, ASMT significantly Increased dP/db,, 
(10.3&6.3% YS -0.2+6.3%), mean aortic pressure (8.7*5.1% vs 1.9+3.0%), and Ees 
(9.5&l% vs -4.6r14.9%) after an average of 8+2weeks follow-up (all the values are 
expressed as percent change from baseline CHF, pcO.05 for each comparison). LV end 
diastolic pressure (-6.9*17.6% YS 3.5*11.4%) and alpha (-4.2*25.7% vs 6.6*15.4%) 
trended to decrease and ejection fraction trended to increase (3.3i3.4 vs -4.2+2.7%) 
although these parameters did not reach significant difference. 
Conclusions: ASMT provided mild improvements in hemodynamics and LV function in 
conscious dogs with chronic heart failure. 
1135-85 Cellular Cardiomyoplasty With Bone Marrow Cells 
Improves Cardiac Performance in Heart Failure Induced 
by Healed Infarct in Rats 
Emerson Olivares, V. Pinho-Ribeiro, J. P. Saar Werneck. R. C. Santos Goldenberg, 
Elizabeth Manes, Hans F. Dohmann, Masako 0. Masuda, Antonio C. Campos de 
Carvalho. lnstituto de Biofisica Carlos Chagas Filho, UFRJ, Rio de Janeiro, Brazil, 
lnstituto do Milenio de Bioengenharia Tecidual, Rio de Janewo, Brazil 
??ackgrounti Pos-infarct congestive heart failure is a leading cause of death in devel- 
oped and developing countries. The heart failure results from the extensive cell death 
and the remodeling process that takes place after the infarct. Published work using cell 
therapies to reconstitute damaged ischemic hearts has focused on animal models of 
acute infarction. Cellular cardiomyoplasty (CCM) has improved heart function in these 
cases. However the efficiency of cell therapies in chronic myocardlal infarcts has not 
been tested. We have now applied bone marrow stromal cell (MSC) therapy to a model 
of healed infarct in rats. Methods and Results: lnbread Male Wistar rats (200 to 2509) 
were anesthetized and the left anterior descending artery was ligated. Four weeks after 
surgery the rats were submitted to CCM. We injected 2O@L of suspension containing 2 
to 5 X ld MSC or culture medium (CM) into the scar tissue. In order to perform a func- 
tional assessment, the rats were submitted to electro (ECG) and echocardiography 
(ECO) two weeks after CCM. The ECG was recorded in the following groups: non-oper- 
ated (n=50), sham-operated (we), infarcted (n=l9) and infarcted and treated wth CM 
(n=6) or MSC (n=7). The EC0 was performed in normal (n=6). sham (n=5). infracted 
(n=17), CM (n=3) and MSC (n=6) groups. The ECG showed a normalization of the AQRS 
(36.50’ *11.77in CCM vs 140.39” il9in CM) and extinction of the Q wave in Dl (0 in 7 
vs 4 in 6 animals), D2 (0 in 7 vs 3 in 8 animals) and Vlat (0 in 7 vs 4 in 6 animals) when 
compared with CM. The EC0 showed no gross change in ventricular geometry but the 
systolic function significantly improved (73.96%*4.65 vs 36.61%*2.63 in ejection frac- 
tion) when compared the MSC with CM. Conclusions: These data suggest that MSC 
can significantly improve cardiac performance even in a short period after CCM (14 
days). This opens interesting therapeutical opportunities for patients with post-ischemic 
congestive heart failure. 
1135-86 Selective Ablation of Insulin Receptor Substrate-l 
Decreases Cardiac Contractility In Vivo Without 
Attenuating PAI-1 Expression or Perivascular Fibrosis 
Satoshi Fuiii Tomoo Furumoto, Hisao Onozuka, Taisei Mikami, Daisuke Goto, Tarikuz 
Zaman, Taeko Sugawara, Yasuo Terauchi. Takashi Kadowaki, Burton E. Sobel, Akira 
Kitabatake, Hokkaido University, Sapporo, Japan 
We have previously shown that coronary perimicrovascular fibrosis is augmented by 
increased cardiac expression of plasminogen activator inhibitor (PAI)-1, the physiologic 
inhibitor of proteo(fibrino)lysis. in genetically obese mice with insulin resistance, hyperin- 
sulinemia and diabetes mellitus. This study was performed to elucidate the potential role 
of insulin receptor substrate-l (IRS-l) mediated signaling. Insulin-injected IRS-1 knock- 
out (KO) mice lack 175-kDa tyrosine-phosphorylated protein (IRS-l) pivotal in many 
types of msulin signaling. IRS-l KO mice exhibit normal glucose tolerance, insulin resis- 
tance and compensatory hyperinsulinemia. At 20 weeks left ventricular (LV) weight in 
IRS-l KO was decreased compared with that in controls (64.1*13.lmg vs 105.7&13.6 in 
C57BU6J, n=20. PcO.001). The diameters of transversely cut myofibers were reduced in 
IRS-l KO (35.lk9.1 pixel vs 39.6e16.2, PcO.001). IRS-1 KO exhibited increased perivas- 
cular fibrosis to lumen ratlo (2.46~0.67 vs control 2.10+0.53. PcO.O5), and increased wall 
to lumen ratio (1.71+0.26 vs control 1.52kO.23, P<O.Ol). The perivascular fibrosis was 
accompanied by persistent cardiac PAI-1 mRNA expression (IRS-l KO 0.43*0.12 AU vs 
control 0.36*0.07. n=3. Northern blot), suggesting persistently diminished pro- 
teo(fibrino)lysis. 15 MHz high resolution echocardiography showed diastolic and systolic 
LV diameters to be increased in IRS-1 KO (LVDd: 3.8+0.1 mm vs control 3.3eo.3. P < 
0.05; LVDs. 1.9+0.2 mm vs control 1.5iO.1, PdO.05) and fractional shortening to be 
decreased (49.5+4.4% vs control 55.6k1.3, P<O.O5), indicating LV dilatation and dys- 
function. Thus, chronic deficiency of IRS-l signaling results in reduced heart size and 
myocyte diameter, and diminishes cardiac contractility under in viva loading condition. 
PAI-1 overexpression and perimicrovascular fibrosis induced by insulin resistance is 
independent of IRS-l signaling. hence sustaining derangements mediated by the com- 
pensatory hyperinsulinemia. This model is useful to examine the role of insulin signaling 
during cardiac adaptation to diabetic stress. 
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